It exerts its antitumor activity by inhibiting multiple receptor tyrosine kinases, including KIT, PDGFRA, PDGFRB, VEGFRs, RET and FLT3, thereby targeting both tumor cell proliferation and angiogenesis (Figure 2 and Figure 3) [32,33,34]. The gene discussed is FLT3; the disease is neoplasm.